Seoul Viosys to Promote Innovative Violeds Technology Solution Proven to Sterilize New Coronaviruses for Air Conditioning and Heating Systems
20.8.2020 15:18:00 EEST | Business Wire | Press release
Seoul Viosys (KOSDAQ:092190), a leading compound semiconductor solution provider, announced that it promotes new Violeds technology solution, the world’s first ultraviolet LED technology proven to sterilize new coronaviruses, for air conditioning and heating systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005452/en/
Air conditioner with Seoul Viosys’ Violeds technology solution (Graphic: Business Wire)
Seoul Viosys will hold a campaign of pilot installation for new Violeds technology solution by August 31st, 2020 focusing on public facilities such as offices, shopping centers, and airport in the world as a part of anti-coronavirus. Inquiries and applications are available on its website (www.seoulviosys.com/en/) and Seoul Viosys’ partners will support additional requests after finishing the first campaign period.
Seoul Viosys provides major manufacturer of air conditioners with optimized UV LED solutions based on successful testing results of 99.9% sterilization of the new coronavirus in 30 seconds by the research group of Korea University. In June, a global air conditioner manufacturer that produces 40 million per year has adopted Violeds technology for its thirty models.
Through the results of testing by Guangzhou Institute of Microbiology in China (CGMT), Gree demonstrates that its new “Fresh Air” air conditioner with Violeds UV LED technology has the performance to sterilize 99.15% of viruses and bacteria, 98% of enteroviruses such as EV71 and H1N1, and 99% of staphylococcus albus bacteria. In addition, it has been proven to sterilize 90% of various harmful viruses in air in 2 hours when using their air conditioners.
Violeds technology has been adopted not only by the Chinese AC manufacturer Gree, but also by a leading in-duct air treatment supplier in the U.S. Seoul Viosys will provide its technology for air conditioners of a leading electronics brand.
Conventional air conditioners typically draw outside air into the AC unit, and discharge that air back into the interior after cooling and filtering, where it is continuously recirculated. This recirculation of indoor air may cause a higher risk of infection through aerosol transmission when viruses are present. The amount of dust and moisture on the cooling filter can also transmit harmful viruses. Conventional filter in air purification system can filter out general droplets or fine dust more than 0.3μm but the viruses such as new coronavirus and SARS virus itself as small as 0.1μm can pass through the HEPA filters as it is.
“As a result of successful production approval to supply Violeds products and expanding customer demand, Violeds UV LEDs have clearly been recognized as essential technology for HVAC (Heating, Ventilation, and Air Conditioning) systems. We believe that our new Violeds technology solution for disinfection of air conditioning and heating systems helps to eliminate viruses in air and protect people from COVID-19 pandemic,” said a representative of Seoul Viosys.
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005452/en/
Contact information
Media Contacts:
Seoul Semiconductor Co., Ltd.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com
North America
Andrew Smith
Email: andrew.smith@seoulsemicon.com
Sales Contacts:
Americas
Mike Berens
mberens@s-et.com
Asia
Dong Ju Kim
djkim@seoulviosys.com
Europe
Marko Hofmann
marko.hofmann@seoulviosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release
Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release
RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom